Your browser doesn't support javascript.
loading
Immunotherapy as an Option for Cancer Treatment.
Rusch, Tillmann; Bayry, Jagadeesh; Werner, Jens; Shevchenko, Ivan; Bazhin, Alexandr V.
Afiliación
  • Rusch T; Department of General, Visceral, and Transplantation Surgery, University Hospital of the LMU, Marchioninistr. 15, 81377, Munich, Germany.
  • Bayry J; INSERM Unité 1138, Centre de Recherche des Cordeliers, Paris, France.
  • Werner J; Department of General, Visceral, and Transplantation Surgery, University Hospital of the LMU, Marchioninistr. 15, 81377, Munich, Germany.
  • Shevchenko I; German Cancer Consortium (DKTK), Partner Site Munich, Munich, Germany.
  • Bazhin AV; Institute for Medical Microbiology, Immunology and Hygiene, Technische Universität München (TUM), Munich, Germany.
Arch Immunol Ther Exp (Warsz) ; 66(2): 89-96, 2018 Apr.
Article en En | MEDLINE | ID: mdl-29026920
ABSTRACT
The progress in melanoma immunotherapy highlights the importance of immunotherapy for cancer treatment. Although the concept of immunotherapy emerged in the beginning of the twentieth century, the end of the century signaled the start of modern immunotherapy, which has recently allowed a staggering progress in the field of cancer immunotherapy. Currently, there is a wide variety of immunotherapeutic approaches and critical improvements are continually being made. Among different immunotherapeutic strategies, therapies based on the blockade of immune checkpoint molecules have shown unparalleled efficacy in late-stage cancer patients. Pre-clinical research using ex vivo and in vivo approaches demonstrates the promise of numerous novel strategies for the immunotherapy of cancer.
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Vacunas contra el Cáncer / Inmunoterapia / Anticuerpos Monoclonales / Neoplasias Límite: Animals / Humans Idioma: En Revista: Arch Immunol Ther Exp (Warsz) Año: 2018 Tipo del documento: Article País de afiliación: Alemania

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Vacunas contra el Cáncer / Inmunoterapia / Anticuerpos Monoclonales / Neoplasias Límite: Animals / Humans Idioma: En Revista: Arch Immunol Ther Exp (Warsz) Año: 2018 Tipo del documento: Article País de afiliación: Alemania